According to data presented at the 2012 American Society of Clinical Oncology Annual Meeting in Chicago. (Abstract # 4655) the presences of liver metastases predicts shorter overall survival in men with metastatic castration-refractory prostate cancer (mCRPC). William Kevin Kelly, DO, Thomas Jefferson University Hospital and the Kimmel Cancer Center at Jefferson, and colleagues from the [...]
According to the results of a study published in the Journal of Clinical Oncology a bone scan index (BSI) can assess response to treatment and predict survival in metastatic hormone-refractory prostate cancer. Men who have castrate resistant or metastatic hormone-refractory prostate cancer that no longer responds to hormonal therapy and has spread to distant sites [...]
Over the years there has been discussion about using Photo Dynamic Therapy to destroy internal tumors, including prostate cancer tumors. Until now it has only been a hope since there is no way to monitor the amount of light that is actually administered to an internal tumor. We currently use laser light in combination with [...]
Prior to the formal review, the FDA has raised questions about the ultimate approval of Amgen’s Xgeva (denosumab) for men with metastatic, advanced prostate cancer who have not yet developed metastasized to the bone. Xgeva has been shown to delay tumors spreading to bones, but it does not extend life, the holy grail of the [...]
Rarely discussed, but very much a potential problem for men with advanced prostate cancer are neurological complications resulting from prostate cancer metastasis. Neurological complications of metastatic prostate cancer require quick treatment to minimize impact on a man, so early recognition is important. Family physicians when faced with a man complaining of low back pain or [...]
One of the major causes of prostate cancer morbidity and mortality is bone metastases. Currently, when it comes to treating prostate cancer metastases we are very limited in effective therapies that actually prolong survival. Kirschenbaum A, etal (Departments of Urology and Medicine Division of Pulmonary Diseases Division of Endocrinology, Metabolism, and Bone Diseases, Mount Sinai [...]
Amgen announced that they have published the results from their Phase 3 trial (the '147 study) that evaluated XGEVA® (denosumab) for use in preventing or delaying the onset of bone metastases in men with non-metastatic castration-resistant prostate cancer (CRPC). The results were published in The Lancet. The study found XGEVA significantly prolonged bone metastasis-free survival, [...]
Cabozantinib (cabo), has many of us prostate cancer survivor, educators and researchers simply scratching their heads. In trials, Cabozantinib demonstrated what some people have characterized as mind boggling activity against bone metastases. In trials the drug led to partial or complete resolution of bone scans in a substantial portion of patients with cancer, including prostate, [...]
Yesterday, Amgen announced that it had submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) to expand its license for XGEVA® (denosumab) to treat men with castrate-resistant prostate cancer to reduce the risk of developing bone metastases. If approved, XGEVA would be the first therapy licensed to prevent or [...]
Sometimes I have heard the question, Where can prostate cancer metastasis (met) be found? Usually, the question really means, how can my met in my spleen or liver (or what ever) come from my prostate cancer? In realty, prostate cancer tumors can develop anywhere in the human body! There was a study of human cadavers [...]
